Regenlab USA

Regenlab USA is a subsidiary of the Swiss-based Regenlab group, a pioneer in the standardized PRP and regenerative medicine device market. The company provides a portfolio of CE-marked and FDA-cleared medical devices that automate the preparation of autologous biological products, aiming to improve reproducibility and clinical outcomes. Its business model revolves around selling proprietary single-use kits and associated centrifuges to clinics and hospitals, generating revenue from consumables. Operating as a private entity, Regenlab has established a commercial presence globally, positioning itself in the growing field of orthobiologics and minimally invasive regenerative procedures.

Proprietary closed-system medical devices for the automated, point-of-care preparation of standardized autologous Platelet-Rich Plasma (PRP) and related formulations. The platform includes single-use kits with separating gel and dedicated centrifuges to ensure consistent composition and yield.

Regenlab competes in the fragmented PRP and autologous cell therapy device market against companies like Arthrex (Angel system), Zimmer Biomet (BioCue), EmCyte, and numerous smaller players. Competition is based on system ease-of-use, consistency of output, clinical data support, price, and distribution strength. The trend towards standardization benefits established players with robust quality systems, but low-cost alternatives remain a threat in price-sensitive segments.